Enanta Pharmaceuticals, Inc. (ENTA)

16,15 -0,30 (-1,82%) Börsenschluss: 04:00PM EDT

Enanta Pharmaceuticals, Inc.

500 Arsenal Street
Watertown, MA 02472
United States
617 607 0800
https://www.enanta.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 145

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jay R. Luly Ph.D.	President, CEO & Director	1,25M	2,03M	1956
Mr. Paul J. Mellett Jr.	Senior VP of Finance & Administration and CFO	666,84k	529,98k	1955
Dr. Yat Sun Or Ph.D.	Senior VP of Research & Development and Chief Scientific Officer	729,31k	424,85k	1952
Mr. Nathaniel S. Gardiner J.D.	Consultant	672,67k	49,14k	1954
Mr. Brendan Luu	Senior Vice President of Business Development	622,86k	N/A	1975
Ms. Jennifer Viera	Senior Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Tara Lynn Kieffer Ph.D.	Senior Vice President of New Product Strategy & Development	496,85k	N/A	1978
Dr. Scott T. Rottinghaus M.D.	Senior VP & Chief Medical Officer	616,73k	N/A	1974

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Enanta Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 5. Die grundlegenden Scores sind Audit: 3, Vorstand: 4, Shareholderrechte: 8, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.